

Reset to improve operational execution and profitability

Q2 report 2025/26

Jakob Just-Bomholt, President and CEO

Tobias Hägglov, CFO

Nov 26, 2025

Important information


This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future events. Although the expectations described in these statements are assumed to be reasonable, there is no guarantee that such forward-looking statements will materialize or are accurate. Since these statements involve assumptions and estimates that are subject to risks and uncertainties, results could differ materially from those set out in the statement. Certain of these risks and uncertainties are described further in the Annual Report in section “Risks and uncertainties”. Elekta undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or stock exchange regulations. This presentation is intended for investors and analysts only. Some products are still in research and/or not cleared/approved in all markets. Cancer statistics are given to show the potential market in the respective area and does not mean that Elekta currently has products to treat these indications.

Initial reflections

Jakob Just-Bomholt
President and CEO

Initial reflections – a fundamentally attractive industry

Cancer care professionals supply vs. demand
Indicative



- Well positioned in an attractive and growing MedTech segment
- Many strongholds in key markets outside U.S.
- 100% focused on radiotherapy, well-recognized brand, and direct sales force
- Current R&D spend sufficient to realize future best-in-class solutions
- Solution sales supplemental by profitable software upgrades and service market

Initial reflections – strong product portfolio logic



Neuro & Brachytherapy

Linac solutions

ONE Software suite

Initial reflections – focus areas to drive improvements




- Gross margin to return towards pre-pandemic levels through continuous engineering and dual-sourcing
- Need for focused and commercially driven innovation agenda with higher speed of delivery
- Grow $\geq$ the overall market. U.S. turnaround required and preserve China position. Stronger commercial execution.
- Apply cost focus across spend and processes
- Simplified organizational structure. Increased speed, accountability and customer centricity.
<

Q2 summary

Jakob Just-Bomholt
President and CEO

Q2 – Sales development by region



Americas – decrease of -8%¹

- Lower sales in U.S. driven by customers awaiting Elekta Evo FDA clearance
- Growth in Latin America

APAC – decrease of -3%¹


- Lower volumes in China impacted by last year's weak order intake
- Growth in India

EMEA – increase of 11%¹

- Continued strong momentum in Europe supported by new product launches

Completed order review – no future structural adjustments are expected

Order backlog as of Q2 FY25/26, SEK M



1.9x
FY24/25 sales

Description of the order backlog review



- Compared to the order review presented in June – firmer interpretation of criteria
- Strong foundation for greater predictability and profitability
- No cash flow effect – no refund of deposits expected
- No impact on revenue growth

Q2 – key takeaways

Continued strong momentum in Europe

1.0
Book-to-bill ratio



Order growth in China. Rolling twelve months at 1.09

1%¹
Net sales growth



Continued strong momentum in Europe supported by new product launches

37.9%
Adj gross margin



Higher GM YoY supported by product launches and price

10.1%
Adj EBIT margin



Reduced R&D spend partly offset by lower capitalization and higher amortization

358 M
SEK cash flow²



SEK 389 M higher cash flow YoY driven by improved working capital

Financial overview

Tobias Häggglöv
CFO

Financial update Q2 25/26

(SEK M)	Q2 25/26	Q2 24/25	Q1 25/26
Net sales	4,070	4,341	3,646
Solutions	2,204	2,458	1,805
Service	1,866	1,883	1,842
COGS ²	-2,529	-2,791	-2,296
Adj. gross margin	37.9%	35.7%	37.0%
Expenses ²	-1,144	-1,113	-1,128
Other	14	-14	13
Adj. EBIT	411	423	235
Adj. EBIT margin	10.1%	9.8%	6.5%
Financial items, net	-80	-113	-83
Income tax	-81	-61	-30
EPS³, SEK	0.60	0.55	0.28
Adj. EPS³, SEK	0.65/0.64	0.63	0.31


Negative FX impact on the P&L

	Q2 25/26	Operations	FX	Q2 24/25
Net sales	4,070	32	-303	4,341
<i>Growth, %</i>	-6.2%	0.7%	-7.0%	-
Adj. gross income	1,541	126	-136	1,551
<i>Adj. gross margin</i>	37.9%			35.7%
<i>Margin impact, ppts</i>	2.1%	2.6%	-0.5%	
Adj. EBIT	411	45	-57	423
<i>Adj. EBIT margin</i>	10.1%			9.8%
<i>Margin impact, ppts</i>	0.4%	1.0%	-0.6%	-

- **Negative FX impact on net sales** driven by stronger SEK vs main revenue currencies USD and EUR
- Margin pressure from **USD depreciation** vs main cost currencies EUR and GBP

Improved cash flow year-over-year



Cash flow after continuous investments Q2 24/25 – Q2 25/26, SEK M



- Improved working capital
- Lower investments
- Cash conversion¹ at 91% (65)
- Improved cash flow after continuous investments by SEK 389 M YoY

Key financial trends

Rolling twelve months, SEK M and margins %



Outlook

H2 25/26

We expect sales in China to start recovering during the second half of 2025/26. Furthermore, we expect continuous negative impact on earnings from FX at current exchange rates and tariffs.

Full year 25/26

Full year outlook reiterated, where net sales in constant currency is expected to grow year-over-year.

Midterm targets

Gross and EBIT margins expected to expand driven by price increases, product launches and volumes, resulting in a stepwise improvement towards our midterm targets to move the gross margin to pre-pandemic levels and an EBIT margin of 14% and higher.

Actions to drive improvements

Jakob Just-Bomholt
President and CEO

Operating model to increase velocity of product development, commercial execution and operational excellence

Elekta has reviewed its operating model...


Simplification

We are simplifying our organizational structure and eliminating complexity in ownership and accountability

Accountability and empowerment

Regions are empowered to take end-to-end accountability, moving our decision-making closer to our customers

Move to a decentralized model with regional-based P&Ls



Upcoming events – strategy update and CMD



<

